Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin Combined With Pucotenlimab in First-Line Treatment-Failed Advanced Biliary Tract Carcinoma
NCT07649980Phase 2Not yet recruiting
- Start
- Jul 2026
- Primary completion
- Jul 2029
01
Overview
A Phase 2 trial of becotatug vedotin, pucotenlimab in biliary tract carcinoma (BTC). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
becotatug vedotinpucotenlimab
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT07649980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07649980.